nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Mesalazine—PPARG—pancreatic cancer	0.00247	0.404	CrCbGaD
L-DOPA—Aminosalicylic Acid—PTGS2—pancreatic cancer	0.00133	0.218	CrCbGaD
L-DOPA—Epinephrine—TNF—pancreatic cancer	0.00126	0.207	CrCbGaD
L-DOPA—Mesalazine—PTGS2—pancreatic cancer	0.00104	0.171	CrCbGaD
L-DOPA—Alopecia—Docetaxel—pancreatic cancer	0.000716	0.00108	CcSEcCtD
L-DOPA—Pruritus—Sunitinib—pancreatic cancer	0.000715	0.00108	CcSEcCtD
L-DOPA—Pain—Irinotecan—pancreatic cancer	0.000712	0.00108	CcSEcCtD
L-DOPA—Constipation—Irinotecan—pancreatic cancer	0.000712	0.00108	CcSEcCtD
L-DOPA—Dyspnoea—Fluorouracil—pancreatic cancer	0.000711	0.00107	CcSEcCtD
L-DOPA—Mental disorder—Docetaxel—pancreatic cancer	0.00071	0.00107	CcSEcCtD
L-DOPA—Somnolence—Fluorouracil—pancreatic cancer	0.000709	0.00107	CcSEcCtD
L-DOPA—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000706	0.00107	CcSEcCtD
L-DOPA—Decreased appetite—Gemcitabine—pancreatic cancer	0.000705	0.00107	CcSEcCtD
L-DOPA—Dyspepsia—Fluorouracil—pancreatic cancer	0.000702	0.00106	CcSEcCtD
L-DOPA—Nausea—Tamoxifen—pancreatic cancer	0.000701	0.00106	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.0007	0.00106	CcSEcCtD
L-DOPA—Fatigue—Gemcitabine—pancreatic cancer	0.000699	0.00106	CcSEcCtD
L-DOPA—Gastritis—Epirubicin—pancreatic cancer	0.000699	0.00106	CcSEcCtD
L-DOPA—Pain—Gemcitabine—pancreatic cancer	0.000693	0.00105	CcSEcCtD
L-DOPA—Constipation—Gemcitabine—pancreatic cancer	0.000693	0.00105	CcSEcCtD
L-DOPA—Nausea—Erlotinib—pancreatic cancer	0.000693	0.00105	CcSEcCtD
L-DOPA—Decreased appetite—Fluorouracil—pancreatic cancer	0.000693	0.00105	CcSEcCtD
L-DOPA—Diarrhoea—Sunitinib—pancreatic cancer	0.000691	0.00104	CcSEcCtD
L-DOPA—Dysgeusia—Docetaxel—pancreatic cancer	0.00069	0.00104	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000688	0.00104	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—pancreatic cancer	0.000687	0.00104	CcSEcCtD
L-DOPA—Feeling abnormal—Irinotecan—pancreatic cancer	0.000686	0.00104	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000685	0.00103	CcSEcCtD
L-DOPA—Dysphagia—Epirubicin—pancreatic cancer	0.000683	0.00103	CcSEcCtD
L-DOPA—Back pain—Docetaxel—pancreatic cancer	0.000682	0.00103	CcSEcCtD
L-DOPA—Pain—Fluorouracil—pancreatic cancer	0.000682	0.00103	CcSEcCtD
L-DOPA—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000681	0.00103	CcSEcCtD
L-DOPA—Muscle spasms—Docetaxel—pancreatic cancer	0.000678	0.00102	CcSEcCtD
L-DOPA—Dizziness—Sunitinib—pancreatic cancer	0.000668	0.00101	CcSEcCtD
L-DOPA—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000668	0.00101	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000667	0.00101	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—pancreatic cancer	0.000665	0.001	CcSEcCtD
L-DOPA—Abdominal pain—Irinotecan—pancreatic cancer	0.000658	0.000994	CcSEcCtD
L-DOPA—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000657	0.000993	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000653	0.000987	CcSEcCtD
L-DOPA—Anaemia—Docetaxel—pancreatic cancer	0.000652	0.000985	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—pancreatic cancer	0.000647	0.000977	CcSEcCtD
L-DOPA—Vomiting—Sunitinib—pancreatic cancer	0.000643	0.000971	CcSEcCtD
L-DOPA—Rash—Sunitinib—pancreatic cancer	0.000637	0.000963	CcSEcCtD
L-DOPA—Dermatitis—Sunitinib—pancreatic cancer	0.000637	0.000962	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000634	0.000958	CcSEcCtD
L-DOPA—Urticaria—Fluorouracil—pancreatic cancer	0.000633	0.000957	CcSEcCtD
L-DOPA—Headache—Sunitinib—pancreatic cancer	0.000633	0.000957	CcSEcCtD
L-DOPA—Syncope—Docetaxel—pancreatic cancer	0.000632	0.000955	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—pancreatic cancer	0.000632	0.000954	CcSEcCtD
L-DOPA—Leukopenia—Docetaxel—pancreatic cancer	0.000631	0.000954	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—pancreatic cancer	0.000631	0.000953	CcSEcCtD
L-DOPA—Palpitations—Docetaxel—pancreatic cancer	0.000623	0.000941	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—pancreatic cancer	0.000621	0.000939	CcSEcCtD
L-DOPA—Loss of consciousness—Docetaxel—pancreatic cancer	0.00062	0.000936	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—pancreatic cancer	0.000618	0.000933	CcSEcCtD
L-DOPA—Cough—Docetaxel—pancreatic cancer	0.000615	0.00093	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—pancreatic cancer	0.000615	0.000929	CcSEcCtD
L-DOPA—Hypersensitivity—Irinotecan—pancreatic cancer	0.000613	0.000927	CcSEcCtD
L-DOPA—Convulsion—Docetaxel—pancreatic cancer	0.000611	0.000923	CcSEcCtD
L-DOPA—Hypertension—Docetaxel—pancreatic cancer	0.000609	0.00092	CcSEcCtD
L-DOPA—Chest pain—Docetaxel—pancreatic cancer	0.0006	0.000907	CcSEcCtD
L-DOPA—Nausea—Sunitinib—pancreatic cancer	0.0006	0.000907	CcSEcCtD
L-DOPA—Asthenia—Irinotecan—pancreatic cancer	0.000597	0.000902	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000597	0.000901	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—pancreatic cancer	0.000592	0.000894	CcSEcCtD
L-DOPA—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000587	0.000888	CcSEcCtD
L-DOPA—Dry mouth—Docetaxel—pancreatic cancer	0.000587	0.000887	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000587	0.000887	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—pancreatic cancer	0.000583	0.000881	CcSEcCtD
L-DOPA—Asthenia—Gemcitabine—pancreatic cancer	0.000582	0.000879	CcSEcCtD
L-DOPA—Confusional state—Docetaxel—pancreatic cancer	0.00058	0.000877	CcSEcCtD
L-DOPA—Oedema—Docetaxel—pancreatic cancer	0.000575	0.000869	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—pancreatic cancer	0.000575	0.000868	CcSEcCtD
L-DOPA—Pruritus—Gemcitabine—pancreatic cancer	0.000574	0.000867	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—pancreatic cancer	0.000571	0.000863	CcSEcCtD
L-DOPA—Diarrhoea—Irinotecan—pancreatic cancer	0.00057	0.000861	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—pancreatic cancer	0.000568	0.000858	CcSEcCtD
L-DOPA—Shock—Docetaxel—pancreatic cancer	0.000566	0.000855	CcSEcCtD
L-DOPA—Pruritus—Fluorouracil—pancreatic cancer	0.000564	0.000852	CcSEcCtD
L-DOPA—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000563	0.000851	CcSEcCtD
L-DOPA—Diarrhoea—Gemcitabine—pancreatic cancer	0.000555	0.000838	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000552	0.000834	CcSEcCtD
L-DOPA—Dizziness—Irinotecan—pancreatic cancer	0.00055	0.000832	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—pancreatic cancer	0.000549	0.00083	CcSEcCtD
L-DOPA—Anorexia—Docetaxel—pancreatic cancer	0.000549	0.000829	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—pancreatic cancer	0.000548	0.000828	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000547	0.000827	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—pancreatic cancer	0.000546	0.000825	CcSEcCtD
L-DOPA—Diarrhoea—Fluorouracil—pancreatic cancer	0.000546	0.000824	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000544	0.000821	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—pancreatic cancer	0.00054	0.000815	CcSEcCtD
L-DOPA—Hypotension—Docetaxel—pancreatic cancer	0.000538	0.000812	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—pancreatic cancer	0.000536	0.000809	CcSEcCtD
L-DOPA—Vomiting—Irinotecan—pancreatic cancer	0.000529	0.0008	CcSEcCtD
L-DOPA—Dizziness—Fluorouracil—pancreatic cancer	0.000527	0.000797	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000525	0.000794	CcSEcCtD
L-DOPA—Rash—Irinotecan—pancreatic cancer	0.000525	0.000793	CcSEcCtD
L-DOPA—Dermatitis—Irinotecan—pancreatic cancer	0.000524	0.000792	CcSEcCtD
L-DOPA—Headache—Irinotecan—pancreatic cancer	0.000522	0.000788	CcSEcCtD
L-DOPA—Insomnia—Docetaxel—pancreatic cancer	0.00052	0.000786	CcSEcCtD
L-DOPA—Paraesthesia—Docetaxel—pancreatic cancer	0.000517	0.000781	CcSEcCtD
L-DOPA—Vomiting—Gemcitabine—pancreatic cancer	0.000516	0.000779	CcSEcCtD
L-DOPA—Dyspnoea—Docetaxel—pancreatic cancer	0.000513	0.000775	CcSEcCtD
L-DOPA—Somnolence—Docetaxel—pancreatic cancer	0.000512	0.000773	CcSEcCtD
L-DOPA—Rash—Gemcitabine—pancreatic cancer	0.000511	0.000772	CcSEcCtD
L-DOPA—Dermatitis—Gemcitabine—pancreatic cancer	0.000511	0.000772	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—pancreatic cancer	0.000508	0.000768	CcSEcCtD
L-DOPA—Headache—Gemcitabine—pancreatic cancer	0.000508	0.000768	CcSEcCtD
L-DOPA—Flushing—Epirubicin—pancreatic cancer	0.000507	0.000766	CcSEcCtD
L-DOPA—Vomiting—Fluorouracil—pancreatic cancer	0.000507	0.000766	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—pancreatic cancer	0.000507	0.000766	CcSEcCtD
L-DOPA—Dyspepsia—Docetaxel—pancreatic cancer	0.000507	0.000765	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—pancreatic cancer	0.000506	0.000764	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000503	0.00076	CcSEcCtD
L-DOPA—Rash—Fluorouracil—pancreatic cancer	0.000503	0.00076	CcSEcCtD
L-DOPA—Dermatitis—Fluorouracil—pancreatic cancer	0.000502	0.000759	CcSEcCtD
L-DOPA—Decreased appetite—Docetaxel—pancreatic cancer	0.0005	0.000756	CcSEcCtD
L-DOPA—Headache—Fluorouracil—pancreatic cancer	0.000499	0.000755	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000499	0.000754	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000497	0.000751	CcSEcCtD
L-DOPA—Fatigue—Docetaxel—pancreatic cancer	0.000496	0.00075	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—pancreatic cancer	0.000496	0.000749	CcSEcCtD
L-DOPA—Nausea—Irinotecan—pancreatic cancer	0.000494	0.000747	CcSEcCtD
L-DOPA—Pain—Docetaxel—pancreatic cancer	0.000492	0.000743	CcSEcCtD
L-DOPA—Constipation—Docetaxel—pancreatic cancer	0.000492	0.000743	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—pancreatic cancer	0.000488	0.000737	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—pancreatic cancer	0.000483	0.000729	CcSEcCtD
L-DOPA—Nausea—Gemcitabine—pancreatic cancer	0.000482	0.000728	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—pancreatic cancer	0.000479	0.000723	CcSEcCtD
L-DOPA—Feeling abnormal—Docetaxel—pancreatic cancer	0.000474	0.000716	CcSEcCtD
L-DOPA—Nausea—Fluorouracil—pancreatic cancer	0.000474	0.000716	CcSEcCtD
L-DOPA—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000471	0.000711	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—pancreatic cancer	0.000469	0.000709	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—pancreatic cancer	0.000469	0.000708	CcSEcCtD
L-DOPA—Tension—Epirubicin—pancreatic cancer	0.000467	0.000705	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—pancreatic cancer	0.000466	0.000704	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—pancreatic cancer	0.000462	0.000698	CcSEcCtD
L-DOPA—Back pain—Epirubicin—pancreatic cancer	0.00046	0.000695	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—pancreatic cancer	0.000457	0.000691	CcSEcCtD
L-DOPA—Abdominal pain—Docetaxel—pancreatic cancer	0.000455	0.000687	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—pancreatic cancer	0.000452	0.000682	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—pancreatic cancer	0.000448	0.000677	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—pancreatic cancer	0.000447	0.000675	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—pancreatic cancer	0.000443	0.000669	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000441	0.000667	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—pancreatic cancer	0.00044	0.000664	CcSEcCtD
L-DOPA—Agitation—Epirubicin—pancreatic cancer	0.000437	0.00066	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—pancreatic cancer	0.000434	0.000655	CcSEcCtD
L-DOPA—Tension—Doxorubicin—pancreatic cancer	0.000432	0.000652	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—pancreatic cancer	0.000431	0.000651	CcSEcCtD
L-DOPA—Malaise—Epirubicin—pancreatic cancer	0.000429	0.000648	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—pancreatic cancer	0.000427	0.000646	CcSEcCtD
L-DOPA—Syncope—Epirubicin—pancreatic cancer	0.000426	0.000644	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—pancreatic cancer	0.000426	0.000643	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—pancreatic cancer	0.000426	0.000643	CcSEcCtD
L-DOPA—Hypersensitivity—Docetaxel—pancreatic cancer	0.000424	0.000641	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—pancreatic cancer	0.000423	0.000639	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—pancreatic cancer	0.00042	0.000635	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—pancreatic cancer	0.000418	0.000632	CcSEcCtD
L-DOPA—Cough—Epirubicin—pancreatic cancer	0.000415	0.000627	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—pancreatic cancer	0.000415	0.000627	CcSEcCtD
L-DOPA—Asthenia—Docetaxel—pancreatic cancer	0.000413	0.000624	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—pancreatic cancer	0.000412	0.000623	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—pancreatic cancer	0.000411	0.00062	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000408	0.000617	CcSEcCtD
L-DOPA—Pruritus—Docetaxel—pancreatic cancer	0.000407	0.000615	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—pancreatic cancer	0.000407	0.000615	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—pancreatic cancer	0.000405	0.000612	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—pancreatic cancer	0.000404	0.000611	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—pancreatic cancer	0.000403	0.00061	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—pancreatic cancer	0.0004	0.000604	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—pancreatic cancer	0.000397	0.0006	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—pancreatic cancer	0.000396	0.000598	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—pancreatic cancer	0.000395	0.000596	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—pancreatic cancer	0.000394	0.000595	CcSEcCtD
L-DOPA—Diarrhoea—Docetaxel—pancreatic cancer	0.000394	0.000595	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—pancreatic cancer	0.000391	0.000591	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—pancreatic cancer	0.000389	0.000588	CcSEcCtD
L-DOPA—Oedema—Epirubicin—pancreatic cancer	0.000388	0.000586	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000387	0.000584	CcSEcCtD
L-DOPA—Cough—Doxorubicin—pancreatic cancer	0.000384	0.00058	CcSEcCtD
L-DOPA—Shock—Epirubicin—pancreatic cancer	0.000382	0.000577	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—pancreatic cancer	0.000381	0.000576	CcSEcCtD
L-DOPA—Dizziness—Docetaxel—pancreatic cancer	0.000381	0.000575	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—pancreatic cancer	0.00038	0.000574	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—pancreatic cancer	0.00038	0.000574	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000375	0.000567	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—pancreatic cancer	0.000375	0.000566	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—pancreatic cancer	0.000373	0.000564	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—pancreatic cancer	0.00037	0.000559	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—pancreatic cancer	0.00037	0.000559	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—pancreatic cancer	0.000366	0.000554	CcSEcCtD
L-DOPA—Vomiting—Docetaxel—pancreatic cancer	0.000366	0.000553	CcSEcCtD
L-DOPA—Rash—Docetaxel—pancreatic cancer	0.000363	0.000548	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—pancreatic cancer	0.000363	0.000548	CcSEcCtD
L-DOPA—Dermatitis—Docetaxel—pancreatic cancer	0.000362	0.000548	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—pancreatic cancer	0.000362	0.000547	CcSEcCtD
L-DOPA—Headache—Docetaxel—pancreatic cancer	0.000361	0.000545	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—pancreatic cancer	0.000359	0.000543	CcSEcCtD
L-DOPA—Shock—Doxorubicin—pancreatic cancer	0.000353	0.000534	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000352	0.000531	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—pancreatic cancer	0.000351	0.00053	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—pancreatic cancer	0.000349	0.000527	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000347	0.000525	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—pancreatic cancer	0.000346	0.000523	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—pancreatic cancer	0.000345	0.000521	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—pancreatic cancer	0.000342	0.000517	CcSEcCtD
L-DOPA—Nausea—Docetaxel—pancreatic cancer	0.000342	0.000516	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—pancreatic cancer	0.000342	0.000516	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—pancreatic cancer	0.000337	0.00051	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—pancreatic cancer	0.000336	0.000507	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000335	0.000506	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—pancreatic cancer	0.000335	0.000506	CcSEcCtD
L-DOPA—Pain—Epirubicin—pancreatic cancer	0.000332	0.000501	CcSEcCtD
L-DOPA—Constipation—Epirubicin—pancreatic cancer	0.000332	0.000501	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—pancreatic cancer	0.000325	0.000491	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—pancreatic cancer	0.000322	0.000487	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—pancreatic cancer	0.00032	0.000484	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—pancreatic cancer	0.00032	0.000483	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—pancreatic cancer	0.000319	0.000482	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000317	0.00048	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—pancreatic cancer	0.000316	0.000478	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—pancreatic cancer	0.000312	0.000472	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.00031	0.000468	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—pancreatic cancer	0.00031	0.000468	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—pancreatic cancer	0.000308	0.000466	CcSEcCtD
L-DOPA—Pain—Doxorubicin—pancreatic cancer	0.000307	0.000464	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—pancreatic cancer	0.000307	0.000464	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—pancreatic cancer	0.000307	0.000464	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000296	0.000447	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000294	0.000444	CcSEcCtD
L-DOPA—Hypersensitivity—Epirubicin—pancreatic cancer	0.000286	0.000432	CcSEcCtD
L-DOPA—Urticaria—Doxorubicin—pancreatic cancer	0.000285	0.000431	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—pancreatic cancer	0.000284	0.000429	CcSEcCtD
L-DOPA—Asthenia—Epirubicin—pancreatic cancer	0.000278	0.000421	CcSEcCtD
L-DOPA—Pruritus—Epirubicin—pancreatic cancer	0.000275	0.000415	CcSEcCtD
L-DOPA—Diarrhoea—Epirubicin—pancreatic cancer	0.000266	0.000401	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000265	0.0004	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—pancreatic cancer	0.000258	0.000389	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—pancreatic cancer	0.000257	0.000388	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—pancreatic cancer	0.000254	0.000384	CcSEcCtD
L-DOPA—Vomiting—Epirubicin—pancreatic cancer	0.000247	0.000373	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—pancreatic cancer	0.000246	0.000371	CcSEcCtD
L-DOPA—Rash—Epirubicin—pancreatic cancer	0.000245	0.00037	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—pancreatic cancer	0.000245	0.000369	CcSEcCtD
L-DOPA—Headache—Epirubicin—pancreatic cancer	0.000243	0.000367	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—pancreatic cancer	0.000237	0.000359	CcSEcCtD
L-DOPA—Nausea—Epirubicin—pancreatic cancer	0.000231	0.000348	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—pancreatic cancer	0.000228	0.000345	CcSEcCtD
L-DOPA—Rash—Doxorubicin—pancreatic cancer	0.000226	0.000342	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—pancreatic cancer	0.000226	0.000342	CcSEcCtD
L-DOPA—Headache—Doxorubicin—pancreatic cancer	0.000225	0.00034	CcSEcCtD
L-DOPA—Nausea—Doxorubicin—pancreatic cancer	0.000213	0.000322	CcSEcCtD
L-DOPA—DRD4—Signaling by GPCR—PIK3CD—pancreatic cancer	6.74e-05	0.000203	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SHH—pancreatic cancer	6.71e-05	0.000202	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.68e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH4—pancreatic cancer	6.67e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KDR—pancreatic cancer	6.66e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IAPP—pancreatic cancer	6.63e-05	0.0002	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.59e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGTR1—pancreatic cancer	6.55e-05	0.000197	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMP—pancreatic cancer	6.47e-05	0.000195	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.47e-05	0.000195	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGTR1—pancreatic cancer	6.46e-05	0.000195	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STK11—pancreatic cancer	6.46e-05	0.000194	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STK11—pancreatic cancer	6.37e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTHLH—pancreatic cancer	6.36e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTCH1—pancreatic cancer	6.36e-05	0.000192	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NFKBIA—pancreatic cancer	6.33e-05	0.000191	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMAD4—pancreatic cancer	6.28e-05	0.000189	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOTCH1—pancreatic cancer	6.27e-05	0.000189	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—pancreatic cancer	6.21e-05	0.000187	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTEN—pancreatic cancer	6.18e-05	0.000186	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CG—pancreatic cancer	6.13e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—NRAS—pancreatic cancer	6.13e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HES1—pancreatic cancer	6.13e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CD—pancreatic cancer	6.07e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGF—pancreatic cancer	6.06e-05	0.000183	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CD—pancreatic cancer	5.98e-05	0.00018	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CB—pancreatic cancer	5.87e-05	0.000177	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.82e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SST—pancreatic cancer	5.82e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.74e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.74e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JAG1—pancreatic cancer	5.69e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH3—pancreatic cancer	5.67e-05	0.000171	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMAD4—pancreatic cancer	5.65e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—pancreatic cancer	5.64e-05	0.00017	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—pancreatic cancer	5.59e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—EGFR—pancreatic cancer	5.59e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMAD4—pancreatic cancer	5.58e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HES1—pancreatic cancer	5.52e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—pancreatic cancer	5.52e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HES1—pancreatic cancer	5.45e-05	0.000164	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CD—pancreatic cancer	5.39e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TERT—pancreatic cancer	5.37e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CNR1—pancreatic cancer	5.37e-05	0.000162	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.34e-05	0.000161	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CB—pancreatic cancer	5.29e-05	0.000159	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—pancreatic cancer	5.28e-05	0.000159	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GLP1R—pancreatic cancer	5.22e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CB—pancreatic cancer	5.22e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CG—pancreatic cancer	5.21e-05	0.000157	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GCG—pancreatic cancer	5.18e-05	0.000156	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HIF1A—pancreatic cancer	5.14e-05	0.000155	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—DPYD—pancreatic cancer	5.13e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TSC2—pancreatic cancer	5.13e-05	0.000154	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—pancreatic cancer	5.08e-05	0.000153	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CD—pancreatic cancer	5.04e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—pancreatic cancer	5.02e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—pancreatic cancer	5.01e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGTR1—pancreatic cancer	4.95e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KDR—pancreatic cancer	4.92e-05	0.000148	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STK11—pancreatic cancer	4.87e-05	0.000147	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	4.87e-05	0.000147	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—pancreatic cancer	4.85e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TERT—pancreatic cancer	4.84e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TERT—pancreatic cancer	4.77e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CB—pancreatic cancer	4.7e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NFKBIA—pancreatic cancer	4.68e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOTCH1—pancreatic cancer	4.63e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIF1A—pancreatic cancer	4.63e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TSC2—pancreatic cancer	4.62e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CD—pancreatic cancer	4.58e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIF1A—pancreatic cancer	4.56e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TSC2—pancreatic cancer	4.55e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CG—pancreatic cancer	4.53e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—NRAS—pancreatic cancer	4.53e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—pancreatic cancer	4.52e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—pancreatic cancer	4.52e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—pancreatic cancer	4.49e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGF—pancreatic cancer	4.48e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—pancreatic cancer	4.46e-05	0.000134	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KDR—pancreatic cancer	4.42e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.4e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—pancreatic cancer	4.37e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—pancreatic cancer	4.36e-05	0.000131	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—pancreatic cancer	4.36e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—pancreatic cancer	4.32e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMAD4—pancreatic cancer	4.27e-05	0.000129	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—pancreatic cancer	4.22e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NFKBIA—pancreatic cancer	4.21e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—pancreatic cancer	4.21e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HES1—pancreatic cancer	4.17e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH1—pancreatic cancer	4.17e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CTNNB1—pancreatic cancer	4.17e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NFKBIA—pancreatic cancer	4.15e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—pancreatic cancer	4.13e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH1—pancreatic cancer	4.11e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—pancreatic cancer	4.09e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—pancreatic cancer	4.08e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—pancreatic cancer	4.08e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—pancreatic cancer	4.06e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGF—pancreatic cancer	4.03e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—pancreatic cancer	4.02e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—pancreatic cancer	4.02e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CB—pancreatic cancer	3.99e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CD—pancreatic cancer	3.98e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGF—pancreatic cancer	3.98e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—pancreatic cancer	3.96e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.94e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—pancreatic cancer	3.9e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—pancreatic cancer	3.84e-05	0.000116	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CD44—pancreatic cancer	3.77e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SRC—pancreatic cancer	3.77e-05	0.000113	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—pancreatic cancer	3.71e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—pancreatic cancer	3.67e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—pancreatic cancer	3.66e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—pancreatic cancer	3.65e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—pancreatic cancer	3.63e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—pancreatic cancer	3.62e-05	0.000109	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GCG—pancreatic cancer	3.62e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CD—pancreatic cancer	3.58e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—pancreatic cancer	3.58e-05	0.000108	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—pancreatic cancer	3.56e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.55e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CD—pancreatic cancer	3.54e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—pancreatic cancer	3.51e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.5e-05	0.000105	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—pancreatic cancer	3.49e-05	0.000105	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSC2—pancreatic cancer	3.48e-05	0.000105	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CB—pancreatic cancer	3.47e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—pancreatic cancer	3.46e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—pancreatic cancer	3.41e-05	0.000103	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—STK11—pancreatic cancer	3.4e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—pancreatic cancer	3.38e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—pancreatic cancer	3.37e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—pancreatic cancer	3.34e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—pancreatic cancer	3.33e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—pancreatic cancer	3.31e-05	9.98e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—pancreatic cancer	3.3e-05	9.94e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.22e-05	9.71e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—pancreatic cancer	3.22e-05	9.7e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—pancreatic cancer	3.19e-05	9.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—pancreatic cancer	3.18e-05	9.58e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKBIA—pancreatic cancer	3.18e-05	9.57e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH1—pancreatic cancer	3.15e-05	9.48e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CB—pancreatic cancer	3.12e-05	9.41e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—pancreatic cancer	3.12e-05	9.39e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—pancreatic cancer	3.11e-05	9.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CB—pancreatic cancer	3.08e-05	9.28e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—pancreatic cancer	3.08e-05	9.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—pancreatic cancer	3.08e-05	9.27e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CTNNB1—pancreatic cancer	3.08e-05	9.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGF—pancreatic cancer	3.04e-05	9.16e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—pancreatic cancer	3.02e-05	9.08e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—pancreatic cancer	3e-05	9.04e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—pancreatic cancer	3e-05	9.03e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—pancreatic cancer	2.98e-05	8.98e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—pancreatic cancer	2.96e-05	8.92e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—pancreatic cancer	2.94e-05	8.86e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TYMS—pancreatic cancer	2.92e-05	8.81e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—pancreatic cancer	2.92e-05	8.81e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—pancreatic cancer	2.9e-05	8.73e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—pancreatic cancer	2.87e-05	8.65e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—pancreatic cancer	2.87e-05	8.63e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—pancreatic cancer	2.86e-05	8.62e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—pancreatic cancer	2.83e-05	8.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—pancreatic cancer	2.8e-05	8.44e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—pancreatic cancer	2.8e-05	8.42e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SRC—pancreatic cancer	2.78e-05	8.37e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—pancreatic cancer	2.77e-05	8.35e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CTNNB1—pancreatic cancer	2.77e-05	8.34e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—pancreatic cancer	2.76e-05	8.31e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CTNNB1—pancreatic cancer	2.73e-05	8.23e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—pancreatic cancer	2.71e-05	8.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—pancreatic cancer	2.71e-05	8.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	2.71e-05	8.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—pancreatic cancer	2.7e-05	8.13e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—pancreatic cancer	2.68e-05	8.08e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.68e-05	8.07e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—pancreatic cancer	2.68e-05	8.07e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—pancreatic cancer	2.67e-05	8.06e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—pancreatic cancer	2.66e-05	8.02e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—pancreatic cancer	2.65e-05	7.98e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	2.65e-05	7.98e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—pancreatic cancer	2.63e-05	7.93e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—pancreatic cancer	2.6e-05	7.82e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SRC—pancreatic cancer	2.5e-05	7.54e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—pancreatic cancer	2.49e-05	7.5e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—pancreatic cancer	2.49e-05	7.49e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SRC—pancreatic cancer	2.47e-05	7.44e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	2.44e-05	7.34e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—pancreatic cancer	2.44e-05	7.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	2.43e-05	7.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—pancreatic cancer	2.41e-05	7.27e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—pancreatic cancer	2.41e-05	7.25e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—pancreatic cancer	2.41e-05	7.24e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—pancreatic cancer	2.38e-05	7.17e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—pancreatic cancer	2.38e-05	7.16e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—pancreatic cancer	2.38e-05	7.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	2.36e-05	7.1e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—pancreatic cancer	2.34e-05	7.05e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—pancreatic cancer	2.3e-05	6.93e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	2.27e-05	6.82e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	2.25e-05	6.78e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—pancreatic cancer	2.24e-05	6.75e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	2.24e-05	6.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—pancreatic cancer	2.21e-05	6.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	2.21e-05	6.65e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—pancreatic cancer	2.19e-05	6.61e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.19e-05	6.59e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.17e-05	6.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—pancreatic cancer	2.16e-05	6.52e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	2.15e-05	6.47e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	2.11e-05	6.37e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.11e-05	6.36e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.09e-05	6.3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—pancreatic cancer	2.07e-05	6.24e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.07e-05	6.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.05e-05	6.17e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—pancreatic cancer	2.05e-05	6.16e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—pancreatic cancer	2.04e-05	6.16e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.04e-05	6.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	1.99e-05	5.99e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—pancreatic cancer	1.96e-05	5.89e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	1.9e-05	5.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SRC—pancreatic cancer	1.89e-05	5.69e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.89e-05	5.68e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	1.88e-05	5.66e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—pancreatic cancer	1.84e-05	5.55e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	1.84e-05	5.54e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—pancreatic cancer	1.82e-05	5.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—pancreatic cancer	1.82e-05	5.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—pancreatic cancer	1.82e-05	5.47e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—pancreatic cancer	1.76e-05	5.31e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—pancreatic cancer	1.74e-05	5.23e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—pancreatic cancer	1.73e-05	5.2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.69e-05	5.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.69e-05	5.09e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1.66e-05	4.99e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.64e-05	4.95e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.63e-05	4.91e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.56e-05	4.71e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—pancreatic cancer	1.56e-05	4.68e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—pancreatic cancer	1.53e-05	4.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.44e-05	4.33e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.42e-05	4.28e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.39e-05	4.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.33e-05	4.01e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.17e-05	3.54e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1e-05	3.02e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—pancreatic cancer	8.19e-06	2.47e-05	CbGpPWpGaD
